✉ Email this page to a colleague
« Back to Dashboard
Enclomiphene is an investigational drug.
There have been 21 clinical trials for Enclomiphene. The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2006.
The most common disease conditions in clinical trials are Hypogonadism, Neoplasm Metastasis, and Diabetes Mellitus. The leading clinical trial sponsors are Repros Therapeutics Inc., Baylor College of Medicine, and Celerion.
Recent Clinical Trials for Enclomiphene
|A Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg Enclomiphene||Repros Therapeutics Inc.||Phase 2|
|Clomiphene Citrate Plus Cabergoline in Treatment of Polycystic Ovary Syndrome||Woman's Health University Hospital, Egypt||Phase 2|
|An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male Subjects After Oral Administration||Celerion||Phase 1|